Àâòîðèçàöèÿ
Ïîèñê ïî óêàçàòåëÿì
Shepherd Ph.S. (ed.), Dean Ch. (ed.) — Monoclonal Antibodies: A Practical Approach
Îáñóäèòå êíèãó íà íàó÷íîì ôîðóìå Íàøëè îïå÷àòêó?
Íàçâàíèå: Monoclonal Antibodies: A Practical ApproachÀâòîðû: Shepherd Ph.S. (ed.), Dean Ch. (ed.) Àííîòàöèÿ: Monoclonal Antibodies: A Practical Approach covers the preparation, testing, derivation, and applications of monoclonal antibodies. New immunological techniques incorporating tried and tested methodologies are described, making the book of interest to established and inexperienced immunologists. Both the standard somatic hybridization technique and recombinant techniques, including the use of phage libraries, for the preparation of rodent and human monoclonal antibodies are described. Protocols for both the small and large scale production are detailed, as well as purification and labelling (with both radioisotopes and non-radioisotopes) methods. The applications of monoclonal antibodies in immunoblotting, enzyme linked immunoassays, immunofluorescence, and FACS analysis are all covered in detail. Finally protocols are given for the use of monoclonal antibodies in rheumatoid arthritis, tissue typing, detecting DNA modified during chemotherapy, and in the clinical analysis of transplantation samples for malignancy. This book will therefore be an invaluable laboratory companion to anyone using monoclonal antibodies in their research.
ßçûê: Ðóáðèêà: Ìåäèöèíà è çäðàâîîõðàíåíèå /Ñòàòóñ ïðåäìåòíîãî óêàçàòåëÿ: Ãîòîâ óêàçàòåëü ñ íîìåðàìè ñòðàíèö ed2k: ed2k stats Ãîä èçäàíèÿ: 2000Êîëè÷åñòâî ñòðàíèö: 479Äîáàâëåíà â êàòàëîã: 16.02.2007Îïåðàöèè: Ïîëîæèòü íà ïîëêó |
Ñêîïèðîâàòü ññûëêó äëÿ ôîðóìà | Ñêîïèðîâàòü ID
Ïðåäìåòíûé óêàçàòåëü
2-mercaptoethanol, reduction-mediated Tc-99m-mAbs 226—227 2-mercaptoethanol, serum supplement 128 2TY media 68 3,3’-diaminobenzidine (DAB) chromogen with HRP 402—403 3,3’-diaminobenzidine (DAB) chromogen, DAB-HRP enhancement 405 3-amino-9-ethylcarbazole, chromogen with HRP 403 3-aminopropyltriethoxysilane, coatings 394 Acusyst culture 138 139 Adhesion molecules, mAbs in RA 454 Affinity chromatography 158—162 Affinity, choice of ligand 160—161 Affinity, immunoaffinity 319—339 Agarose, embedding cells 427 Agrobacterium tumefaciens-mediated transformation in tobacco 188—192 196—199 Airlift fermenters 136 Alkaline phosphatase, anti-alkaline phosphatase, (APAAP) method, immunocytochemical staining 400—401 Alkaline phosphatase, AP-conjugated secondary Abs 280 Alkaline phosphatase, Fast Red TR salt chromogen 404—405 Alkaline phosphatase, IgG labelling 304—305 Alkaline phosphatase, mAb labelling 240 277 Alkaline sarkosyl 16 Amine group-specific dye derivatives 356 Ammonium sulfate, precipitation 144 157—158 Animal models, organ transplantation and mAb therapy 435—436 Anion exchange, chromatography 165—166 Anti-IL6 and -IL6R mAbs 453—454 Anti-receptor Abs, ligand binding assays 17 Anti-TNF-alpha mAbs 452—453 Antibody genes 33—34 Antibody labelling see “Specific types of label” Antibody therapies avoiding antiglobulin response 434 Antibody therapies, depletion vs non-depletion 433—434 Antibody therapies, immunosuppression vs immunological tolerance 432—433 Antibody therapies, mAbs in organ transplantation 431—448 Antibody therapies, radioimmunotherapy 229—231 Antibody therapies, rheumatoid arthritis 449—461 Antibody-ribosome-mRNA, (ARM) complexes 91—109 Antibody-ribosome-mRNA, amplification of genetic information 102—103 Antibody-ribosome-mRNA, antigen selection 98—103 Antibody-ribosome-mRNA, antigen selection recovery of DNA 100—103 Antibody-ribosome-mRNA, ARM specificity 105—106 Antibody-ribosome-mRNA, cycles and cloning 103—105 Antibody-ribosome-mRNA, generation by coupled transcription/translation 96—98 Antigen binding, immunoaffinity chromatography 331—333 Antigens immobilized, immunotubes 71—74 Antigens labelling, competitive binding immunoassays 309—311 Antigens on live cells 5—6 Antigens or streptavidin-coupled magnetic beads 98—99 Antigens, antigen-mAb complexes, recognition 277 Antigens, coating multiwell plates 12—13 Antigens, preparation for immunization 5 Antigens, reconstitution, immunoaffinity chromatography 335—336 Antigens, retrieval high temperature (HTAR) 397—398 Antigens, retrieval proteolysis 396—398 Antiglobulin response, antibody therapies 434 Arabidopsis, antibody fragment production 182—183 ARM cycle 92 ARM display 91—109 ARM examples 105—107 ARM method 93—105 ARM method, primer design and vH/K construction 93—96 ARM troubleshooting 107 (see also “Antibody-ribosome-mRNA (ARM) complexes”) Ascitic route of hybridoma, production 126 At-211, radioimmunotherapy, applications 230 Avidin-biotin complex detection 398—400 B lymphocytes and myeloma cells 1—23 B lymphocytes and myeloma cells, preparation for fusion 10 B lymphocytes, Epstein — Barr virus transformation 114—116 B lymphocytes, lymphoblastoid cell lines (B-LCL) 114—117 B lymphocytes, lymphoblastoid cell lines (B-LCL), fusion with murine myeloma cells 118—120 B lymphocytes, mRNA, vH/K construction, ARM display 93—96 B lymphocytes, rodents as source 1—3 B lymphocytes, selection of antigen-specific B cells by rosetting 116—117 Bacteria minimal medium 70 BCIP/NBT substrate 280 Beta-glucuronidase (gus) 187 Bifunctional chelating (BFC) agents 219 229 Binary vector, components 189—192 Bioreactors stirred 134—135 (see also “Culture systems”) Bioreactors, airlift 136 Bioreactors, fluidized bed 142—143 Bioreactors, membrane (miniPerm) 139—140 Bioreactors, Siran fixed porous beads 141—142 Biotin labelling 243 305—306 Biotinylated proteins, coupling to streptavidin coupled Dynabeads 99 Biotinylated proteins, tyramine, preparation 406—407 Biotinylation of antigen 74—76 BiP 183 BIRR-1, murine anti-ICAM-1 mAb 454 Bismuth-213, radioimmunotherapy applications 230 BLAST, database search program 63 Blood group antigens, human mAbs 111—123 Blood, fluorescence activated cell analysis (FACS) 371—389 Blood, normal values 377 Bolton and Hunter reagent, radiolabelling of mAbs 216 307 Bombardment-mediated gene transfer 192—196 Bone marrow, COBE-2991, buffy coat preparation 380—381 Bone marrow, COBE-2991, mononuclear cell fraction (MNC) 381—382 Bone marrow, fluorescence activated cell analysis (FACS) 371—389 Bone marrow, haematopoietic transplantation, Campath-1M, paediatric 383—384 Bone marrow, PBSC harvests, CD34 quantitation 379—380 Bone marrow, progenitor cell content, analysis 377—382 Bone marrow, T cell depletion 383—384 Bovine IgG potential contamination of media 152—153 Bovines, myeloma cell lines 3 BrdUrd flow cytometry in vitro incorporation 345 BrdUrd flow cytometry, background 343—345 BrdUrd flow cytometry, cell kinetics 341—343 BrdUrd flow cytometry, denaturation of BrdUrd 347 BrdUrd flow cytometry, examples 350—352 BrdUrd flow cytometry, fixation and staining procedures 345—349 BrdUrd flow cytometry, technique 341—353 BstN1 frequent-cutting enzyme 55 BstN1 frequent-cutting enzyme, restriction enzyme mix 56 Buffers, blocking buffer 277 278—279 Buffers, Harms buffer 269 Buffers, immunoassays 315—316 Buffers, lysis 266—268 Buffers, mixed micelle detergent (RIPA) 266—268 292 Buffers, SDS-PAGE 267 Buffers, sodium azide-phosphate-buffered saline (PBSA) 14 Buffers, TAE buffer 28 Buffers, TE buffer 28 Buffers, ThermoPol reaction buffer 35 C-erbB2 proto-oncogene as immunogen 4 Caesium chloride, isopycnic centrifugation 46—49 Cameras, CCD and colour cameras 365—367 Campath-1H in RA 456 Campath-1H, haematopoietic transplantation 383—384 Campath-1H, mAb therapies, antiglobulin response 434 Campath-1H, mAb therapies, rheumatoid arthritis 433 Campath-1H, renal allografts 445 Cancer, fluorescence activated cell analysis (FACS) 371—389 Canonical residues 60 Carbodiimide coupling, immunoaffinity chromatography 324—325 Carbohydrate coupling, immunoaffinity chromatography 325—326 Catalysed enzyme reporter deposition (CARD) 79 Cation exchange, chromatography 162—165 CCD cameras 365—367 CD25 mAb, clinical use 437 442 443 CD25 mAb, experimental models 443 CD28 and CD40, co-stimulation 443—444 CD3 mAb animal studies 437—438 CD3 mAb clinical use of anti-CD3 mAb 439—440 CD34 determinant, FACS 378—380 CD4 mAb, clinical trials 442 CD4mAb, cM-T412, anti-CD4 mAb with human IgGl 456 CD4mAb, experimental models 440—442 CD5-plus 455—456 CD7 mAb, anti-CD7 mAbs 455 CD8 mAb 440 cDNA cDNA: mRNA hybrid 31—32 CDw52 mAb, human IgGl Fc see “Campath-1H” CEA, anti-CEA antibodies 80 Cell adaptation, low levels of serum in culture 128—129 Cell fixation, BrdUrd flow cytometry technique 345—346 Cell fixation, immunofluorescence 358 Cell fixation, paraffin wax embedded tissues 392—393 (see also “Fixatives”) Cell fusion in vitro somatic hybridization 11 Cell kinetics monitoring with BrdUrd-labelled nuclei 341—343 Cell labelling in vivo immunolabelling 368—369 Cell labelling, surface labelling 359 Cell lysates, controlled to produce a post-nuclear supernatant homogenate 269—270 Cell lysates, preparation 266—268 Cell lysates, preparation rigorous whole cell lysis 267—268 Cell lysates, sequential extraction 268—269 Cell staining procedures 346—349 Cell storage, long-term; liquid nitrogen 18 Cellular antigens 265—296 Cellular antigens, 2D PAGE 283—286 Cellular antigens, detection by immunoblotting 270—283 Cellular antigens, detection by immunoprecipitation 289—295 Cellular antigens, detection under disruptive conditions 292 Cellular antigens, subcellular localization of proteins 287 Chaotropic ions 334—335 Chaperone molecules 183 Chemifluorescence enhanced 279 Chemiluminescence enhanced 278 Chemotherapy, antibodies to modified DNA 411—430 Chemotherapy, detection of chemically modified DNA in lymphocytes 411—430 Chloramine-T labelling with I-125 209—210 307—308 Chloronaphthol substrate 280 Chothia scheme, CDR loops 60 61 Chromatography, affinity 158—162 Chromatography, equipment 153—156 Chromatography, hydrophilic interaction 173 Chromatography, hydrophobic interaction 169—172 Chromatography, immobilized metal affinity 166—168 Chromatography, immunoaffinity 319—339 Chromatography, integrated systems 154 Chromatography, ion exchange 162—166 Chromatography, liquid, general principles 155—156 Chromatography, monitors 154 Chromatography, nickel-chelate 88 Chromatography, other 172—173 Chromatography, size exclusion 168—169 Chromatography, TLC, radiochemical purity 212—213 Chronic lymphocytic leukaemia 382 cM-T412, anti-CD4 mAb with human IgG1 456 Colloidal gold, light and electron microscopy 247—263 Colorimetry, signal detection 280 Colour cameras 367 Competitive binding, immunoassays 309—311 Competitive inhibition, immunoassay 317 Competitive radioimmunoassays 21 Complementarity-determining regions and humanized antibodies 58—65 Complementarity-determining regions, acceptor frameworks 62 Complementarity-determining regions, defined (Kabat; Chothia) 59—60 Complementarity-determining regions, grafting, humanization of recombinant ntibodies 25—27 Complementarity-determining regions, loop definitions 61 Complementarity-determining regions, Vernier zone 64 Confocal laser scanning, microscopy 364—365 Contact scheme, CDR loops 60 61 Copper-67, radioimmunotherapy applications 230 Coupling matrices, immunoaffinity chromatography 322 Crown gall disease see “Agrobacterium tumefaciens” Cryopreservation 122—123 Cryosections, methods for EM immunogold probes 251—255 CsCl banding, DNA preparation 47—49 Culture media, 2TY media 68 Culture media, Dulbecco’s modified Eagle’s medium (DMEM) 4 Culture media, HAT selection medium 11 Culture media, minimal medium, bacteria 70 Culture media, serum levels and replacements 127—128 Culture media, tobacco 197—198 Culture supernatants 149—180 Culture supernatants, concentration using hollow fibre device 151—153 Culture supernatants, problems with purification 151—153 Culture systems, Acusyst culture 138 139 Culture systems, comparisons 145 Culture systems, culture plates and flasks 129—130 Culture systems, high cell density 137—143 Culture systems, hollow fibre 138 139 Culture systems, membrane (miniPerm) 139—140 Culture systems, non-stirred systems 135—137 Culture systems, packed beds 140—142 Culture systems, perfusion (high cell density) 137—143 Culture systems, roller bottle culture 135 Culture systems, stationary cultures 129—131 Culture systems, stirred cultures 131—135 Culture systems, Tecnomouse 138—139 (see also “Bioreactors”) Cyanogen bromide, coupling, immunoaffinity chromatography 322 Cytokines, anti-cytokine mAbs in RA 452—454 Cytokines, anti-cytokine mAbs in RA, anti-IL6 and -IL6R 453—454 Cytokines, anti-cytokine mAbs in RA, anti-TNF-alpha 452—453 Cytokines, mononuclear cell fraction (MNC) 384—389 Cytokines, mononuclear cell fraction (MNC), preparation 386 Cytokines, mononuclear cell fraction (MNC), staining 387 DB3, anti-progesterone antibodies 105—106 DB3, DB3R vH/K, selection from libraries 106—107 Decalcification 392—393 Dextran, detection methods, immunocytochemistry 400 Dialyser, hollow fibre dialyser assembly 153 Digoxigenin labelling 244 DNA preparation using CsCl banding 47—49 DNA staining, drug-DNA adducts 426—427 DNA staining, embedding cells 428—429 DNA, chemically modified antibodies vs modified polymeric DNA 412—414 DNA, chemically modified antibodies, applications 412 DNA, chemically modified antibodies, detection of low frequencies 414 DNA, chemically modified antibodies, ELISA 415—426 DNA, chemically modified antibodies, inducing tolerance 434—435 DNA, chemically modified antibodies, preparation 414—415 DNA, chemically modified antibodies, screening hybridomas 415 DNA, chemically modified antibodies, types 412 DNA, chemically modified detection in lymphocytes, patients undergoing, chemotherapy 411—430 DNA, linker DNA preparation 37—41 Dounce homogenization 269 DTPA anhydride 219—222 Dulbecco’s modified Eagle’s medium (DMEM) 4 Dulbecco’s phosphate-buffered saline 359 Dynabeads, antigen selection 98 Dynamic culture systems 135—137 Electron microscopy, immunofluorescence 355—370 Electron microscopy, immunogold probes 247—263 Electron microscopy, methods PLT 248—249 255—256 Electron microscopy, methods thawed cryosections 251—255 Electron microscopy, pre-embedding labelling 249—250 Electron microscopy, surface labelling 250 Electroporation competent cells, library construction 52—54 Electrotransfer and plating 54—55 Electrotransfer from gels to membranes 273—276 Electrotransfer immunoblotting, troubleshooting 282—283 ELISA, cell ELISA 78 ELISA, competitive inhibition 317 ELISA, IgGs, generic method 175—177 ELISA, phage ELISA 83—84 ELISA, protein A/G assays, reagent choice 175—176 ELISA, quantification of DNA, analysis of data 425—426 ELISA, quantification of DNA, competitive assays 419—425 ELISA, quantification of DNA, direct binding assays 418—419 ELISA, quantification of DNA, maximization of immunoreactivity 420—422 ELISA, quantification of DNA, modifications 415—426 ELISA, quantification of DNA, well coating 416—417 ELISA, sandwich ELISA 311—315 ELISA, soluble (scFv) ELISA 85—87 Elution regimes 72 Embedding cells, agarose 427 Embedding cells, paraffin wax, fixation procedures 392—393 Embedding cells, staining DNA 428—429
Ðåêëàìà
|
|
Î ïðîåêòå